JP2024504923A5 - - Google Patents

Info

Publication number
JP2024504923A5
JP2024504923A5 JP2023541711A JP2023541711A JP2024504923A5 JP 2024504923 A5 JP2024504923 A5 JP 2024504923A5 JP 2023541711 A JP2023541711 A JP 2023541711A JP 2023541711 A JP2023541711 A JP 2023541711A JP 2024504923 A5 JP2024504923 A5 JP 2024504923A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
cdr1
cdr2
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2023541711A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024504923A (ja
Filing date
Publication date
Priority claimed from PCT/US2021/044858 external-priority patent/WO2022032045A1/en
Application filed filed Critical
Priority claimed from PCT/US2022/012049 external-priority patent/WO2022150788A2/en
Publication of JP2024504923A publication Critical patent/JP2024504923A/ja
Publication of JP2024504923A5 publication Critical patent/JP2024504923A5/ja
Withdrawn legal-status Critical Current

Links

JP2023541711A 2021-01-11 2022-01-11 受容体ペア形成に関する組成物および方法 Withdrawn JP2024504923A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202163136098P 2021-01-11 2021-01-11
US202163135884P 2021-01-11 2021-01-11
US63/135,884 2021-01-11
US63/136,098 2021-01-11
PCT/US2021/044858 WO2022032045A1 (en) 2020-08-05 2021-08-06 IL10Rα/IL2Rγ SYNTHETIC CYTOKINES
USPCT/US2021/044858 2021-08-06
PCT/US2022/012049 WO2022150788A2 (en) 2021-01-11 2022-01-11 Compositions and methods related to receptor pairing

Publications (2)

Publication Number Publication Date
JP2024504923A JP2024504923A (ja) 2024-02-02
JP2024504923A5 true JP2024504923A5 (cg-RX-API-DMAC7.html) 2025-01-17

Family

ID=82358792

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023541711A Withdrawn JP2024504923A (ja) 2021-01-11 2022-01-11 受容体ペア形成に関する組成物および方法

Country Status (5)

Country Link
US (1) US20250163162A1 (cg-RX-API-DMAC7.html)
EP (1) EP4274616A2 (cg-RX-API-DMAC7.html)
JP (1) JP2024504923A (cg-RX-API-DMAC7.html)
CA (1) CA3204162A1 (cg-RX-API-DMAC7.html)
WO (1) WO2022150788A2 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12540188B2 (en) 2020-08-05 2026-02-03 Synthekine, Inc. IL10Rα/IL2Rγ synthetic cytokines
CA3190415A1 (en) * 2020-08-05 2022-02-10 Synthekine, Inc. Il2rb/il2rg synthetic cytokines
WO2022031885A2 (en) 2020-08-05 2022-02-10 Synthekine, Inc. Il10ra binding molecules and methods of use
JP7743500B2 (ja) 2020-08-05 2025-09-24 シンセカイン インコーポレイテッド Il10受容体結合性分子および使用方法
WO2024040195A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
US20260209367A1 (en) * 2024-11-22 2026-07-23 Gilead Sciences, Inc. SINGLE IMMUNOGLOBULIN DOMAIN BISPECIFIC ANTIBODIES AGAINST IL 10R alpha AND beta SUBUNITS AND METHODS OF USE

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4569794A (en) 1984-12-05 1986-02-11 Eli Lilly And Company Process for purifying proteins and compounds useful in such process
IL104570A0 (en) 1992-03-18 1993-05-13 Yeda Res & Dev Chimeric genes and cells transformed therewith
US5320663A (en) 1992-07-02 1994-06-14 E. I. Du Pont De Nemours And Company Method of obtaining lead and organolead from contaminated media using metal accumulating plants
US5650234A (en) 1994-09-09 1997-07-22 Surface Engineering Technologies, Division Of Innerdyne, Inc. Electrophilic polyethylene oxides for the modification of polysaccharides, polypeptides (proteins) and surfaces
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5800819A (en) 1996-01-25 1998-09-01 National Institute For Pharmaceutical Research And Development Federal Ministry Of Science And Technology Piper guineense, pterocarpus osun, eugenia caryophyllata, and sorghum bicolor extracts for treating sickle cell disease
US6017060A (en) 1997-11-26 2000-01-25 Trw Vehicle Safety Systems Inc. Pressure relief plug
US6682736B1 (en) 1998-12-23 2004-01-27 Abgenix, Inc. Human monoclonal antibodies to CTLA-4
NZ517202A (en) 1999-08-24 2004-05-28 Medarex Inc Human CTLA-4 antibodies and their uses
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
ES2367430T3 (es) 2002-12-23 2011-11-03 Wyeth Llc Anticuerpos contra pd-1 y sus usos.
JP2008501706A (ja) * 2004-06-04 2008-01-24 ジェネンテック・インコーポレーテッド 疾患の治療方法
EP3530736A3 (en) 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
KR101704734B1 (ko) 2005-07-01 2017-02-09 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
NZ597098A (en) 2006-09-28 2013-05-31 Merck Sharp & Dohme Use of pegylated il-10 to treat cancer
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
MX356367B (es) 2008-12-09 2018-05-25 Genentech Inc Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t.
US20130022629A1 (en) 2010-01-04 2013-01-24 Sharpe Arlene H Modulators of Immunoinhibitory Receptor PD-1, and Methods of Use Thereof
CN103079644B (zh) 2010-06-11 2017-02-15 协和发酵麒麟株式会社 抗tim‑3抗体
US9163087B2 (en) 2010-06-18 2015-10-20 The Brigham And Women's Hospital, Inc. Bi-specific antibodies against TIM-3 and PD-1 for immunotherapy in chronic immune conditions
US8907053B2 (en) 2010-06-25 2014-12-09 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds
US20120201746A1 (en) * 2010-12-22 2012-08-09 Abbott Laboratories Half immunoglobulin binding proteins and uses thereof
US9669071B2 (en) 2011-03-11 2017-06-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for stimulating T lymphocytes with IL-2
WO2013006490A2 (en) 2011-07-01 2013-01-10 Cellerant Therapeutics, Inc. Antibodies that specifically bind to tim3
KR101815323B1 (ko) 2011-09-08 2018-01-05 삼성전자주식회사 복수의 무선 전력 수신기로부터 무선 전력 공급기에 신호를 송신하는 방법 및 장치
CN104245726A (zh) 2012-03-29 2014-12-24 奥瑞基尼探索技术有限公司 来自人pd1的bc环的免疫调节环状化合物
US10010588B2 (en) 2013-08-30 2018-07-03 Armo Biosciences, Inc. Methods of using pegylated interleukin-10 for treating hyperlipidemia
MX2016002544A (es) 2013-09-04 2016-06-17 Squibb Bristol Myers Co Compuestos utiles como inmunomoduladores.
PL3099717T3 (pl) 2014-01-31 2019-10-31 Novartis Ag Cząsteczki przeciwciała dla TIM-3 i ich zastosowanie
US9850225B2 (en) 2014-04-14 2017-12-26 Bristol-Myers Squibb Company Compounds useful as immunomodulators
US10042852B2 (en) 2014-09-29 2018-08-07 Telefonaktiebolaget Lm Ericsson (Publ) Interference and/or power reduction for multiple relay nodes using cooperative beamforming
AU2015264953B2 (en) 2014-10-01 2017-05-25 Ocean Floor Geophysics Inc. Compensation of magnetic data for autonomous underwater vehicle mapping surveys
MY193661A (en) 2014-11-06 2022-10-24 Hoffmann La Roche Anti-tim3 antibodies and methods of use
US10618970B2 (en) 2015-02-03 2020-04-14 Armo Biosciences, Inc. Method of treating cancer with IL-10 and antibodies that induce ADCC
KR102894264B1 (ko) 2015-03-10 2025-12-02 오리진 온콜로지 리미티드 면역조절제로서의 1,2,4-옥사다이아졸 및 티아다이아졸 화합물
EA201791621A1 (ru) 2015-03-10 2018-02-28 Ауриджен Дискавери Текнолоджис Лимитед 3-замещенные-1,2,4-оксадиазольные и тиадиазольные соединения в качестве иммуномодуляторов
EP3297672B1 (en) * 2015-05-21 2021-09-01 Harpoon Therapeutics, Inc. Trispecific binding proteins and methods of use
WO2016191587A1 (en) 2015-05-28 2016-12-01 Armo Biosciences, Inc. Pegylated interleukin-10 for use in treating cancer
CA2995120A1 (en) 2015-08-25 2017-03-02 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
US11087249B2 (en) 2016-05-24 2021-08-10 Ciambella Ltd. Method and apparatus for triggering execution of a workflow over a network
IL321812A (en) 2017-08-03 2025-08-01 Synthorx Inc Cytokine complexes for the treatment of autoimmune diseases
CN111315398A (zh) 2017-11-10 2020-06-19 阿尔莫生物科技股份有限公司 白介素-10与免疫检查点途径抑制剂的组合的组合物和使用方法
GB201903767D0 (en) * 2019-03-19 2019-05-01 Quadrucept Bio Ltd Multimers, tetramers & octamers

Similar Documents

Publication Publication Date Title
JP7840836B2 (ja) 改善された血清アルブミン結合性免疫グロブリン可変ドメイン
US20240124584A1 (en) Igm fc and j-chain mutations that affect igm serum half-life
RU2770209C2 (ru) Терапевтические антитела против лиганда cd40
JP2009523459A5 (cg-RX-API-DMAC7.html)
WO2021216468A1 (en) Human tigit specific single domain antibodies and methods of use
JP6162319B2 (ja) ヒト化抗n2抗体
RU2003126168A (ru) Терапевтические связывающие молекулы
JP2024537779A5 (cg-RX-API-DMAC7.html)
BR112020003628A2 (pt) anticorpo anti-pacap
CA3134224A1 (en) Composition for preventing or treating brain and nervous system disease
JP2025517120A5 (cg-RX-API-DMAC7.html)
US20230391863A1 (en) Bifunctional antagonists of activin and tumor necrosis factor alpha and uses thereof
US20240343788A1 (en) Novel bifunctional multispecific antagonists capable of inhibiting multiple ligands of tgf-beta family and uses thereof
CN115698077A (zh) 结合bcma的单可变结构域及抗原结合分子
KR102753603B1 (ko) 신규한 Nav1.7 모노클로날 항체
JP2024546916A5 (cg-RX-API-DMAC7.html)
JP7691977B2 (ja) 抗tirc7抗原結合タンパク質
JP3773556B2 (ja) 抗アレルギー剤
AU2021365528A9 (en) Bifunctional antagonists of tumor necrosis factor-alpha and transforming growth factor-beta and uses thereof
RU2024119559A (ru) ПОЛИПЕПТИДЫ, СОДЕРЖАЩИЕ ОДИНОЧНЫЕ ВАРИАБЕЛЬНЫЕ ДОМЕНЫ ИММУНОГЛОБУЛИНА, НАЦЕЛИВАЮЩИЕСЯ НА TCRαβ, CD33 и CD123
RU2025119828A (ru) Связывающие белки, связывающие pd-1×4-1bb
WO2026064762A1 (en) Anti-myostatin antibodies and methods
CN118488971A (zh) 优化的Multabody构建体、组合物和方法
CN118745231A (zh) 抗ror1和cd3的双特异性抗体及其应用
US20200223927A1 (en) Methods and compositions for treating multiple sclerosis